Maxcyte (MXCT) Research & Development (2020 - 2026)

Maxcyte (MXCT) has reported Research & Development for 7 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 32.16% year-over-year to $4.3 million in Q2 2026; TTM through Jun 2026 was $16.8 million, a 32.56% decrease from a year earlier, with the FY2025 full-year figure at $20.8 million, down 21.9% from the prior year.
• Research & Development was $4.3 million for Q2 2026 at Maxcyte, up from $3.9 million in the prior quarter.
• Over five years, Research & Development peaked at $7.4 million in Q1 2024 and troughed at $3.3 million in Q4 2025.
• A 5-year average of $5.7 million and a median of $6.1 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 69.45% in 2022 and slumped 48.48% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $5.7 million in 2022, then increased by 25.65% to $7.2 million in 2023, then retreated by 10.06% to $6.5 million in 2024, then plunged by 48.48% to $3.3 million in 2025, then climbed by 27.53% to $4.3 million in 2026.
• The last three Research & Development figures came in at $4.3 million (Q2 2026), $3.9 million (Q1 2026), and $3.3 million (Q4 2025), per Business Quant data.